In early 2024, Dr. Elena Vasquez, a population geneticist at a mid-sized state university, opened her monthly budget spreadsheet and saw that her lab's targeted sequencing project had become unaffordable. The campus core facility had raised its per-base price by roughly 30–50%, a change that pushed the cost of her rare-disease gene panel beyond what her NIH grant could absorb. She had to make a choice: reallocate funds to a larger, common-variant study or abandon the mutation hunt entirely. She chose the former, and the rare-variant project went into indefinite hibernation.

The Invoice That Stopped a Mutation Hunt

Vasquez's lab had spent three years assembling a cohort of 200 families with an undiagnosed neurodevelopmental disorder. They had collected DNA samples, built a phenotype database, and designed a targeted panel covering 500 candidate genes. The plan was to sequence these samples at high depth to find rare, likely pathogenic variants. The per-base price increase, applied uniformly across all projects, meant the panel would cost roughly $3,000 per sample instead of $2,000. For 200 samples, that was an extra $200,000.

The core facility's new price schedule was not unusual. Many sequencing cores at mid-sized universities have raised prices in recent years, citing amortization of instruments, service contracts, and reagent costs. Vasquez's grant, originally funded for a two-year window, had a fixed budget. She could apply for a supplement, but the timeline for review was longer than her project's runway. The alternative was to sequence fewer samples, which would cripple the statistical power she needed to detect rare variants.

She decided to pivot. The lab's remaining funds went to a genome-wide association study of a common metabolic trait, a project with larger sample sizes and a higher likelihood of producing publishable results. The rare-mutation panel was shelved, its primers and probes sitting in a freezer. Vasquez told her graduate student, "We'll come back to this if funding allows," but both knew the window was closing.

The story is not unique. Across the country, labs studying rare diseases are being squeezed as cores adjust pricing. The economics of sequencing have shifted in ways that favor scale and common variants, often at the expense of the deep, targeted sequencing that rare-mutation discovery requires.

Why Sequencing Cores Raise Prices

Sequencing cores operate as shared facilities that recover costs through user fees. Their budgets include instrument purchase or lease, maintenance contracts, reagents, and staff salaries. When a core's instruments age, service contracts become more expensive, and reagent prices rise with inflation. Core directors face institutional pressure to break even or generate surplus, and they often adjust per-base rates accordingly.

Demand shifts also play a role. As large consortia and clinical diagnostics companies order massive quantities of sequencing, cores can offer lower per-base prices for volume. This creates a two-tier market: big projects get economies of scale, while small, targeted projects pay premium rates. A core director at another university, who asked not to be named, explained that "to keep the machine running, we need a steady stream of high-throughput runs. Small panels are harder to schedule and less efficient, so we price them higher."

Reagent costs are another factor. Sequencing chemistries have not dropped in price as steeply as the cost per base suggests. A run that yields 600 gigabases costs roughly the same whether you use it for one whole genome or a hundred targeted panels. The per-sample cost of targeted sequencing is dominated by library preparation and capture, not by the sequencing itself. Cores that price per base may inadvertently penalize targeted projects, which use fewer bases per sample but require more hands-on time.

Institutional politics also matter. Cores often receive subsidies from their university, but these subsidies can be reduced in tight budget years. When that happens, core directors must raise fees to cover the gap. Vasquez's core had been operating at a deficit for two years, and the 30–50% increase was an attempt to balance the books. The decision was made by a committee, not by a single person, and it applied uniformly across all users.

Economists who study research infrastructure note that such pricing models are rarely optimized for discovery. They incentivize large, repetitive projects that can amortize fixed costs, while penalizing the small, exploratory studies that often generate novel biological insights. The result is a system that favors incremental progress over high-risk, high-reward science.

The Rare-Mutation Blind Spot

Rare-mutation studies have inherent statistical challenges. With small sample sizes, the power to detect a variant that contributes to a phenotype is low. Effect sizes for rare variants can be large, as in Mendelian disorders, but for complex traits, they are often modest. Replication is difficult because the same variant may not appear in another cohort.

Phenotype heterogeneity further clouds signals. A rare variant might cause epilepsy in one family but intellectual disability in another, depending on genetic background and environmental factors. This makes it hard to aggregate data across studies. As a result, many funding agencies prioritize common-variant association studies, which have a clearer path to genome-wide significance.

The bias is not just financial. Journals are more likely to publish a study with a Manhattan plot and a handful of loci than a study that reports a single novel mutation in a small family. Publication pressure pushes researchers toward designs that are more likely to produce statistically significant results, even if those results are less biologically meaningful.

Vasquez's experience reflects this blind spot. Her rare-mutation panel was designed to find variants with large effect sizes, but the cost increase made it impossible to sequence enough samples to meet the threshold for a meaningful result. The common-variant study, by contrast, had a clear path to publication with a modest sample size.

The irony is that rare variants are often the most actionable. They can lead to targeted therapies, as in the case of cystic fibrosis or sickle cell disease. But the economic and publishing incentives do not align with this reality.

Evidence That Rare Variants Matter

Despite the challenges, the evidence that rare variants drive disease is strong. Mendelian disorders, such as Huntington's disease and cystic fibrosis, are caused by single mutations with near-complete penetrance. Exome sequencing studies have identified causal genes for epilepsy and intellectual disability, with de novo mutations accounting for a substantial fraction of severe cases.

In epilepsy, for example, several studies have found that de novo mutations in genes like SCN1A and KCNQ2 explain a significant proportion of early-onset cases. These findings have immediate clinical utility, guiding treatment and genetic counseling. The effect sizes are large, often with odds ratios in the hundreds.

Population isolates provide another line of evidence. The Finnish Disease Heritage, a set of rare genetic disorders enriched in Finland due to founder effects, has been a treasure trove for gene discovery. By studying a population with reduced genetic diversity, researchers have mapped dozens of recessive diseases that would be nearly impossible to find in a more heterogeneous population.

These examples show that rare variants are not just noise; they are the substrate of many human diseases. The challenge is that finding them requires deep sequencing of many samples, which is exactly what a per-base price increase makes unaffordable.

The Cost-Per-Variant Calculation

When evaluating sequencing strategies, the relevant metric is not cost per base but cost per variant discovered. A targeted panel that sequences 500 genes at high depth may cost more per base than a whole-genome run, but it can identify a causal variant with far fewer samples.

Whole-genome sequencing, despite its high per-base cost, is often more efficient for rare-variant discovery because it covers the entire genome, including regulatory regions. However, the cost per sample is much higher, and the analysis is more complex. Targeted panels offer a middle ground, focusing on known disease genes at a fraction of the cost.

Pricing models that ignore discovery yield are misleading. A core that charges $0.01 per base might seem cheap, but if a project requires 100 million bases per sample to find one variant, the effective cost per variant is high. Conversely, a targeted panel that sequences 1 million bases per sample might find a variant in 20 samples, making the cost per variant much lower.

Vasquez's panel was designed with this logic in mind. She estimated that sequencing 200 samples at 150x depth would cost around $400,000, and she expected to find at least 10 novel likely pathogenic variants. That works out to $40,000 per variant, which compares favorably to the cost of a large GWAS that might identify only a handful of common variants with small effects.

But the core's pricing structure did not account for this. The per-base increase made her panel prohibitively expensive, even though the cost per variant would have been reasonable. This mismatch between pricing and discovery yield is a systemic problem.

How Labs Adapt to Shrinking Budgets

Labs have developed strategies to cope with rising costs. Some share cores across institutions, negotiating batch runs to reduce per-sample prices. Vasquez considered joining a consortium that pooled samples from multiple labs, but the logistics of sharing clinical data were daunting.

Others switch to cheaper chemistries, such as using a lower-cost polymerase or reducing sequencing depth. This can work for some applications, but for rare-variant detection, depth is critical. Lowering depth from 150x to 80x could miss a heterozygous variant in a mosaic sample.

Applying for supplementary grants is another avenue, but the success rate is low and the timeline is long. Vasquez submitted a supplement request to her NIH institute, but she was told that funds were tight and the review would take six months. Her project could not wait that long.

Collaborating with clinical partners is a more promising approach. Clinical labs often have access to patient samples and may be willing to fund sequencing in exchange for research findings. Vasquez had been in talks with a nearby hospital, but the negotiations fell apart when the hospital's own budget was cut.

These adaptations are stopgap measures. They do not address the underlying issue of pricing models that penalize small, targeted studies. Until cores adopt tiered pricing that reflects the value of discovery, labs will continue to drift toward common-variant research.

The Human Cost of Shelved Panels

Behind the budget spreadsheets and pricing schedules are families waiting for answers. For many rare diseases, a genetic diagnosis is the first step toward understanding the condition, accessing appropriate care, and connecting with support networks. When a lab like Vasquez's shelves its panel, those families lose a potential path to clarity.

Consider the case of a family with a child suffering from undiagnosed seizures. The child has undergone countless tests, seen multiple specialists, and exhausted standard diagnostic workups. A targeted gene panel could identify a mutation in a gene like SCN1A, leading to a diagnosis of Dravet syndrome. That diagnosis would not only explain the symptoms but also guide treatment choices, as certain antiseizure medications are contraindicated in this condition. Without sequencing, the family remains in limbo, facing years of uncertainty and potentially harmful trial-and-error treatments.

Rare disease advocacy groups have long recognized this gap. Organizations like the Rare Genomics Institute and the Undiagnosed Diseases Network have stepped in to provide sequencing for families who cannot afford it or whose doctors cannot secure funding. These efforts are commendable, but they are not scalable. They rely on philanthropic donations and volunteer time, and they cannot replace the systematic, hypothesis-driven research that labs like Vasquez's conduct.

Moreover, the economic argument for rare-variant research extends beyond individual diagnoses. Each novel gene discovered can illuminate fundamental biological pathways, with implications for common diseases. For instance, mutations in the gene PCSK9, initially found in families with extreme cholesterol levels, led to the development of a new class of cholesterol-lowering drugs that benefit millions. Similarly, rare variants in the SLC2A1 gene, causing GLUT1 deficiency syndrome, have informed our understanding of glucose transport in the brain, with potential relevance to epilepsy and other neurological conditions.

The loss of these discoveries is not just a scientific setback; it is a public health opportunity cost. When pricing models discourage rare-variant studies, they slow the translation of genetic insights into therapies. The next blockbuster drug might be hiding in a rare mutation that never gets sequenced because a core raised its per-base price.

Rethinking Pricing and Funding

To address the imbalance, some have proposed alternative pricing models. One idea is to base fees on the biological question rather than the number of bases. For example, a core could charge a flat rate per sample for targeted panels, reflecting the hands-on time and library prep, while charging per base only for whole-genome runs. This would make the cost of a targeted panel more predictable and less sensitive to per-base price fluctuations.

Another approach is to create a subsidy pool for exploratory studies. Cores could allocate a small percentage of their revenue from large projects to fund discounted or free sequencing for pilot studies and rare-disease projects. This would not only support high-risk science but also foster a culture of innovation within the core facility.

Funding agencies also have a role to play. The NIH and other bodies could offer specific grant mechanisms for rare-variant discovery, with budgets that account for realistic sequencing costs. They could also require cores to disclose their pricing structures in grant proposals, allowing reviewers to assess feasibility. Some agencies have already begun to address this, with programs like the NIH's Common Fund supporting undiagnosed diseases, but more needs to be done.

Researchers themselves can advocate for change. By organizing and communicating their needs to core directors and institutional leadership, they can push for pricing that reflects the value of discovery. Professional societies, such as the American Society of Human Genetics, could issue guidelines for fair core pricing and lobby for funding policies that support rare-variant research.

Ultimately, the goal is to create a system where the cost of sequencing does not dictate the science. The per-base price is a convenient metric, but it is not the only one. By shifting the conversation to cost per variant and the broader value of discovery, we can ensure that rare-mutation hunts are not silenced by a budget spreadsheet.

What This Means for Gene Discovery

The silent loss of rare-variant studies has consequences. Each shelved panel represents a potential diagnosis for a family, a new drug target, or a mechanistic insight. The publication bias toward common variants skews our understanding of the genetic architecture of disease.

Transparent core pricing is a first step. Cores should publish their cost structures and explain how they set rates. Researchers could then make informed decisions about which projects are feasible. But transparency alone is not enough.

Funding incentives should reward discovery, not just productivity. Agencies could offer supplements for high-risk projects or require cores to offer discounts for exploratory studies. Some have proposed a tiered pricing model, where the first few runs are cheaper to encourage pilot data, and later runs are priced at full cost.

Vasquez's lab has not given up. She is exploring a collaboration with a core at a different university that offers a discount for academic users. But the uncertainty has taken a toll. Her graduate student has shifted to a project on common variants, and the rare-mutation panel remains in the freezer.

The next breakthrough in rare disease genetics may not come from a large consortium. It may come from a small lab with a clever design and a core that is willing to work with them. Until the economics change, that lab will be the exception, not the rule.